NewAmsterdam Pharma Co NV (FRA:KH6) Stock News, Headlines & Updates
NewAmsterdam Pharma Co NV Stock News from GuruFocus
- 1
Jul 22, 2025
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 | NAMS Stock News
GuruFocus News • 7:21am
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data at AAIC 2025 | NAMS stock news
GuruFocus News • 7:01am
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
Marketwired • 7:00am
Jul 17, 2025
NAMS: Goldman Sachs Initiates Coverage on NewAmsterdam Pharma Co | NAMS Stock News
GuruFocus News • 7:00am
Goldman Sachs Initiates Coverage of NewAmsterdam Pharma (NAMS) with Neutral Rating | NAMS Stock News
GuruFocus News • 5:47am
Jun 27, 2025
NAMS: Upcoming Conference Call Hosted by Cantor Fitzgerald | NAMS Stock News
GuruFocus News • 3:45pm
Jun 17, 2025
Citigroup Initiates Coverage on NAMS with a Buy Rating | NAMS Stock News
GuruFocus News • 7:30am
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News
GuruFocus News • 4:47am
Jun 12, 2025
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | NAMS Stock News
GuruFocus News • 6:00am
Jun 10, 2025
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News
GuruFocus News • 10:02am
Jun 09, 2025
Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Positive Outlook | NAMS Stock News
GuruFocus News • 3:46pm
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News
GuruFocus News • 6:46am
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial | NAMS Stock News
GuruFocus News • 6:20am
NewAmsterdam Pharma Co NV (NAMS) Announces Promising Phase 3 Trial Results for Alzheimer's Biomarker Reduction | NAMS stock news
GuruFocus News • 6:01am
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
Marketwired • 6:00am
Jun 05, 2025
NewAmsterdam Pharma Co NV (NAMS) Announces R&D Day Event for Analysts and Investors | NAMS stock news
GuruFocus News • 7:01am
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
Marketwired • 7:00am
Jun 04, 2025
NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Cantor Fitzgerald | NAMS Stock News
GuruFocus News • 5:16am
May 27, 2025
NewAmsterdam Pharma Co NV (NAMS) Announces Participation in Key Investor Conferences | NAMS stock news
GuruFocus News • 8:21am
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
Marketwired • 7:00am
May 14, 2025
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
Marketwired • 7:00am
May 09, 2025
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insight
GuruFocus News • 11:30pm
May 08, 2025
Needham Maintains Buy Rating but Lowers Price Target for NAMS | NAMS Stock News
GuruFocus News • 2:32pm
NAMS Focuses on Growth and Innovation with Strong Financial Position | NAMS Stock News
GuruFocus News • 8:06am
NewAmsterdam Pharma Co NV Q1 2025 Earnings: Revenue Surges to $3.0 Million, Beating Estimates; Net Loss Narrows Significantly
GuruFocus News • 7:31am
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Marketwired • 7:00am
May 07, 2025
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News
GuruFocus News • 7:11am
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 202
GuruFocus News • 6:30am
May 02, 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NAMS Stock News
GuruFocus News • 3:18pm
Apr 30, 2025
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Marketwired • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news